Pink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo

Generics Bulletin

Medtech Insight

Edwards Keeps TAVR Going During COVID-19 Surge

Jan 29 2021

• By Reed Miller

Post pandemic vision; economic outlook after Coronavirus COVID-19 crisis concept — • Source: shutterstock.com

Related Content

FDA Expands TAVR Indication To Low-Risk Patients

Aug 16 2019

Harpoon Finds Its Whale: Edwards Spends Up To $250m For Beating-Heart Mitral Repair Option

Dec 12 2017

CMS Extends National Medicare Coverage For Transcatheter Mitral Valve Repair

Jan 20 2021

JPM 2021: Medtronic, Biogen, Edwards LifeSciences, Guardant Health, Illumina

Jan 12 2021

Edwards Returns To Growth In The Third Quarter

Oct 22 2020

Boston Scientific Gives Up On Lotus Edge TAVR

Nov 17 2020

Related Companies

Edwards Lifesciences Corp.

Medtronic plc

Boston Scientific Corporation

Additional Topics

Sales & Earnings Coronavirus COVID-19 Business Strategies Research & Development Commercial Companies Clinical Trials Cardiovascular Cardiology Medical Device

More from Cardiology

More from Device Area

Twitter feed RSS feed RSS feed

About

About UsOpens in new window
Meet the Team
AdvertiseOpens in new window
Contact Us

Account

My Account
My View
Email Preferences
Start Free TrialOpens in new window

More

Medtech Top 100 Ranking
Data Trackers
FDA Warning Letters

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window